Bracket, a specialty services provider, has been acquired by Parthenon Capital Partners, a growth-oriented private equity firm based in Boston and San Francisco, from Express Scripts Holding Company.

Bracket assists pharmaceutical companies and CROs maximize clinical data integrity and ultimately achieve greater certainty in trial outcomes with a range of solutions that span both eClinical and Scientific Services. Bracket’s team of experts has worked on more than 1,100 successful trials across 47 therapeutic areas with an emphasis on the central nervous system. Bracket is a member of the Electronic Patient-Reported Consortium, a program run by the Critical Path Institute.

“As an independent company, Bracket will now have the autonomy, flexibility and resources to pursue our growth strategy and continue to provide best in breed technology enabled solutions for our clients,” said Catherine Spear, Bracket’s president. “We are excited to partner with Parthenon given their extensive investment experience in healthcare and deep understanding of technology’s power to advance medicine. They have a long track record of partnering with growth-oriented healthcare companies like Bracket and we welcome their support as we look to grow Bracket globally through continued investment in innovative technology and cutting-edge science.”

David Ament, managing partner at Parthenon, said, “We have been studying the clinical trials specialty services market for several years and believe Bracket offers a unique and highly compelling set of solutions to the industry.”

“We believe life sciences companies will continue to increase their utilization of technology enabled solutions designed to optimize trial efficiency and ensure data integrity,” said Bradley Sloan, principal at Parthenon. “Bracket is well-positioned to further its market leadership in these areas and help increase precision in clinical trials for years to come.”

The company also announced that Ian Lennox has joined the Bracket board of directors as executive chairman. Lennox has invested, built and been engaged in a number of innovative companies in the clinical trial and pharmaceutical services industry, including Drug Royalty (DRI), MDS Pharma Services, Aptiv Solutions and Celerion.